Investment Rating - The report maintains an optimistic outlook for the pharmaceutical industry, projecting growth opportunities across various segments by 2025 [10][12]. Core Insights - The current valuation of the pharmaceutical sector is low, with public funds under-allocating to this sector. Positive macroeconomic factors are expected to drive growth [10]. - The report emphasizes a shift from quantity to quality in the domestic innovative drug sector, highlighting the importance of differentiated and internationalized pipelines [10]. - The medical device market is showing signs of recovery, particularly in imaging equipment and home medical devices, with significant growth potential [10]. - The report identifies a favorable environment for the CXO and life sciences services sectors, anticipating a rebound in domestic investment and a return to high growth by 2025 [10]. - The traditional Chinese medicine sector is expected to benefit from policy changes and market dynamics, with specific companies recommended for investment [12]. - The report highlights the potential for the blood products industry to grow, particularly in the context of domestic production capabilities and the impact of U.S. tariffs on imported products [30][43]. Market Overview - The report notes that the Chinese albumin market is heavily reliant on imports, with 2024 projections indicating a market size of approximately 235 billion yuan, reflecting an 8.4% decline from the previous year [15][30]. - The domestic albumin market is expected to see a shift towards increased local production due to changing tariff structures and supply chain dynamics [30][43]. - The report outlines the competitive landscape for albumin, indicating that domestic products are poised to capture market share as U.S. imports decline [30][39]. Specific Company Insights - The report identifies several key companies in the innovative drug space, including 恒瑞, 百济, and 贝达, which are expected to lead in product development and profitability [10]. - In the medical device sector, companies like 迈瑞 and 联影 are highlighted for their growth potential due to ongoing equipment upgrades and international expansion [10]. - The report also discusses the emerging opportunities for companies involved in recombinant human albumin production, particularly those utilizing innovative production methods [50][55].

证券研究报告 | 医药生物 | 2025年4月19日 www.hczq.com 华创医药投资观点&研究专题周周谈·第122期 对美关税反制，国产白蛋白市场展望 本周周专题联系人：朱珂琛 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号: S0360520110002 邮箱: zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号: S0360520110004 邮箱: lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号：S0360523080008 邮箱：wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号: S03605240700 ...

Core Points - The core viewpoint of the news is the performance and structure of the Industrial Bank's Frontier Medical Stock A fund, highlighting its recent decline and overall returns since inception [1][2]. Group 1: Fund Performance - On April 17, Industrial Bank Frontier Medical Stock A (001717) fell by 0.42%, with a latest net value of 2.81 yuan, marking a cumulative decline of 0.95% over three consecutive trading days [1]. - Since its establishment in February 2016, the fund has achieved a cumulative return of 181.20% with a total fund size of 91.35 billion yuan [1]. Group 2: Holder Structure - As of the end of 2024, institutional investors hold 348 million shares of the fund, accounting for 10.02% of the total shares, while individual investors hold 3.124 billion shares, making up 89.98% of the total [1]. Group 3: Fund Management - The current fund manager, Zhao Bei, has extensive experience in the healthcare sector and has been managing the fund since February 3, 2016 [2]. - As of December 31, 2024, the top ten holdings of the fund account for a total of 50.04%, with significant positions in companies such as Heng Rui Pharmaceutical (9.52%) and Ke Lun Pharmaceutical (5.65%) [2].

Summary of Conference Call Records Company and Industry Overview - The discussion primarily revolves around the pharmaceutical and medical device industries, with a focus on small-cap companies and their innovative capabilities. The emphasis is on the potential for significant investment returns from these smaller firms as they introduce world-class innovations [1][2]. Key Points and Arguments Innovation and Market Dynamics - The rise of world-class innovations from smaller companies is highlighted, suggesting that these firms are increasingly capable of delivering significant breakthroughs in technology and products, which can lead to substantial investment opportunities [1]. - The current state of small-cap companies in the Hong Kong stock market is described as severely undervalued, indicating a potential for significant price reversals and investment elasticity [2]. Clinical Trials and Product Development - There is a notable increase in the number of clinical trials being conducted by both new and established companies, with specific mention of companies like 百利链 and 克隆伯泰 showing promising stock performance and long-term value potential [3]. - The report mentions ongoing clinical trials in the oncology sector, particularly the oral formulations and their third-phase data, which are seen as key developments in the industry [2]. Equipment and Device Sector - The medical equipment sector is expected to experience growth due to the recovery of bidding processes and inventory adjustments, with companies like 联营, 开力, and 奥华 being highlighted as key players to watch [4]. - The report notes that the equipment industry is likely to see a positive growth trajectory in the first quarter of the year, driven by increased demand and inventory management [4]. Market Trends in Traditional Chinese Medicine - The traditional Chinese medicine sector is experiencing a downturn, with a projected decline in retail sales for 2024, particularly in categories like cold and flu medications [25][26]. - Despite the overall decline, certain products within the sector, such as 阿胶, are noted for their strong market performance, indicating a mixed outlook for the industry [27]. Investment Opportunities - The report suggests that there are significant investment opportunities in the pharmaceutical sector, particularly in companies with strong clinical capabilities and financial resources, which are expected to benefit from new regulatory measures and market dynamics [12][15]. - The potential for mergers and acquisitions in the life sciences sector is also discussed, with companies like 必得医药 and 奥普麦 actively pursuing strategic acquisitions to enhance their market positions [21]. Economic Indicators and Investment Climate - The investment climate for the biopharmaceutical sector is reported to be improving, with significant increases in investment amounts both domestically and internationally, indicating a robust growth outlook for the sector [18][19]. - The report highlights a positive trend in orders and revenue for the CXO sector, with expectations for many companies to return to double-digit growth in the coming years [19]. Other Important Insights - The introduction of new regulatory measures, such as the three-year data protection period for certain generic drugs, is expected to create a more favorable competitive environment for leading companies in the pharmaceutical industry [12][15]. - The report emphasizes the importance of monitoring the performance of small-cap companies and their innovative products, as they may present significant investment opportunities in the evolving market landscape [3][4]. This summary encapsulates the key insights and trends discussed in the conference call, providing a comprehensive overview of the current state and future outlook of the pharmaceutical and medical device industries.

Core Insights - The company achieved operating revenue of 8.401 billion yuan in 2024, a slight decrease of 0.34% year-on-year, while net profit attributable to shareholders increased by 45.74% to 648 million yuan [1] - The company reported a significant increase in profitability, with a gross margin of 43.46%, despite a year-on-year decline of 1.36 percentage points, primarily due to a decrease in the revenue share of high-margin cardiovascular products [1] Business Performance - The revenue from the cardiovascular product line decreased by 17.45% year-on-year to 2.195 billion yuan, while the orthopedic series saw a significant decline of 52.80% to 103 million yuan [2] - The anti-malarial products generated revenue of 133 million yuan, reflecting a year-on-year growth of 45.89%, and the "Kunzhong Medicine 1381" division's digestive system products achieved revenue of 549 million yuan, up 2.46% [2] - The company is focusing on building a premium national medicine platform through its "Kunzhong Medicine 1381" series, which includes various traditional Chinese medicine products [2] Strategic Developments - The company completed the acquisition of a 51% stake in China Resources Shenghuo, marking a critical phase in the integration with China Resources Sanjiu [2] - A five-year strategic plan (2024-2028) was released, positioning the company as a leader in the elderly health industry, leveraging the "1246" model from China Resources Group [2] Investment Outlook - The investment rating remains "strongly recommended," with expectations for the core product, the blood clotting series, to gain traction post-collection renewal, benefiting from the advantages of focusing on the aging population [3] - Projected net profits for 2025-2027 are estimated at 778 million, 891 million, and 1.011 billion yuan, representing year-on-year growth rates of 20.0%, 14.6%, and 13.5% respectively [3]

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]

21世纪经济报道记者 闫硕 北京报道 3月26日，北京市医保局局长马继业表示，今年将再新设100亿元规模的医药并购基金，构建全周期接续 支持、市区协同的医药健康产业基金体系。 同日，上海生物医药并购私募基金合伙企业（有限合伙）正式成立。企查查显示，该基金由上海医药 （601607）（601607）、新华保险（601336）（601336）、东富龙（300171）（300171）、君实生物 （688180）等共同出资，出资额达46.6亿元。 事实上，2024年以来，国家和地方陆续出台重磅政策鼓励并购重组：新"国九条""科创板八条""并购六 条"陆续发布；随后，深圳、上海、郑州等地发布三年行动方案；北京、广东等地举办并购重组座谈 会，多措并举活跃并购重组市场。 医疗战略咨询公司Latitude Health创始人赵衡向21世纪经济报道记者指出，医药行业并购重组是未来的 趋势。随着市场持续出清和调整，并购将会越来越多。不同公司将会根据自身发展策略关注细分市场。 海通证券研报指出，并购重组有望提升并购重组市场效率，帮助上市公司向新质生产力方向转型升级。 分领域来看，并购重组有望在医疗器械、中药、医疗服务、血制品与科研 ...

昆药集团: 昆药集团关于2025年度担保计划的公告 证券代码：600422 证券简称：昆药集团 公告编号：2025-020号 昆药集团股份有限公司关于 2025 年度担保计划的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 昆药集团本部 2025 年度对子公司担保计划额度为人民币 2.25 亿元，均为连带责 任担保，该等担保涉及被担保单位及相关担保明细如下所列： | | | | | | 单位：人民币 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 担保额度 | 是 | | | | | | 被担保 | | | | | | | | | | | 占上市公 | 否 | | | | | 担保方 | 方最近 | | | | | | | 担保 | | | 截止目前 | 本次担保 | 司最近一 | 关 | 是 | 否有 ? 2025 年度，为适应昆药集团股份有限公司（以下简称"本公司"、"公司" 或"昆药集团"）及相关下属公司业务发展需要 ...

重要内容提示： 召开的日期时间：2025 年 4 月 18 日 10 点 00 分 召开地点：云南省昆明市国家高新技术开发区科医路 166 号昆药集团股份有 限公司管理中心 (五) 网络投票的系统、起止日期和投票时间。 昆药集团: 昆药集团关于召开2025年第三次临时股 东大会的通知 证券代码：600422 证券简称：昆药集团 公告编号：2025-022 昆药集团股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 4 月 18 日 至 2025 年 4 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、 ...